Price T Rowe Associates Inc Celldex Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,087,208 shares of CLDX stock, worth $114 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
3,087,208
Previous 422,293
631.06%
Holding current value
$114 Million
Previous $16.7 Million
673.6%
% of portfolio
0.02%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CLDX
# of Institutions
207Shares Held
61.2MCall Options Held
291KPut Options Held
246K-
Wellington Management Group LLP Boston, MA7.65MShares$283 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.51MShares$167 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.65MShares$135 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.12MShares$115 Million2.11% of portfolio
-
Polar Capital Holdings PLC London, X03.06MShares$113 Million0.8% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.73B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...